1.CHINA PH ARMACY Volume 33,Number 8,April 30,2022 Semimonthly Table of Contents Expert consensus on prescription review rules of proton pump inhibitors
China Pharmacy 2022;33(8):897-910
In order to further s tandardize the clinical application of proton pump inhibitors and provide reference for prescription suitability review ,under the guidance of Guiding Principles for Clinical Use of Proton Pump Inhibitor which was promulgated by the General Office of National Health Commission of the People ’s Republic of China ,Pharmaceutical Admini- stration Committee of Chongqing Hospital Association initiates “the formulation Project on Prescription Review Rules for Proton Pump Inhibitors ”. The First Affiliated Hospital of the Army Medical University takes the lead and cooperates with clinical experts , pharmaceutical experts and evidence-based experts from many domestic medical institutions to discuss the indications ,usage and dosage,medication for special groups and drug interactions of proton pump inhibitors ,and finally forms this consensus. The main contents of the consensus include the basic prescription review rules of omeprazole ,esmeprazole,pantoprazole,rabeprazole, lansoprazole and iprazole (including injection and oral preparations ,calculated by common name ),and 12 prescription review recommendations for some clinical applications not covered on the basic prescription review rules ,in order to provide reference for medical institutions at all levels.
2.Expert consensus on pharmaceutical active consultation service in medical institutions
Association Pharmaceutical CHONGQING ; Institutions THE
China Pharmacy 2024;35(23):2837-2843
OBJECTIVE To further standardize the implementation and management standards of pharmaceutical active consultation in medical institutions and provide a reference for providing high-quality pharmaceutical services. METHODS Guided by the Chongqing Pharmaceutical Association and led by the Third Affiliated Hospital of Chongqing Medical University, a panel of experts consisting of pharmaceutical and medical management professionals from multiple medical institutions was established to discuss the basic requirements, service processes, quality control, and evaluation improvement of pharmaceutical active consultation. The drafting team then organized, summarized, analyzed and revised the opinions, and provided feedback to ultimately form a consensus. RESULTS & CONCLUSIONS This consensus provides a detailed exposition of the basic requirements, service processes, quality control, and evaluation improvement of pharmaceutical active consultation, offering standards for the implementation of pharmaceutical active consultation in medical institutions in China, which is of major implications for strengthening the pharmaceutical service capabilities of medical institutions.